No Data
No Data
Express News | Entrada Therapeutics Inc - Expects Cash Runway to Extend Into Q2 2027 - SEC Filing
Express News | Entrada Therapeutics Inc - to Reduce Workforce by Approximately 20% Under New Plan - SEC Filing
Express News | Entrada Therapeutics Inc - Approves Strategic Plan Focusing on Dmd Programs - SEC Filing
Why Investors Shouldn't Be Surprised By Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) 27% Share Price Plunge
H.C. Wainwright Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Maintains Target Price $20
Express News | HC Wainwright & Co. Reiterates Buy on Entrada Therapeutics, Maintains $20 Price Target